Table 1. Survival data in studies that compared sublobar resection to lobectomy for patients with NSCLC.
| Author [year] | Study design | No. of Patients | Stage | Compromised vs. intentional | Type of sublobar resection | Mortality (%) |
5-YSR |
Local rec. rate |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lobectomy | Sublobar resection | Lobectomy (%) | Sublobar resection (%) | P | Lobectomy (%) | Sublobar resection (%) | P | ||||||||
| LCSG [1995] | Pros.; phase III | 247 | IA | Intentional | Wedge: 40; Seg.: 82 | 1.6 | 0.8 | 69 | 60 | 0.08 | 6.4 | 17 | 0.079 | ||
| Koike [2003] | Pros.; non-randomized | 233 | IA (≤2 cm) | Intentional | Wedge: 14; Seg.: 60 | 0 | 0 | 90.1 | 89.1 | NS | 1.3 | 2.7 | NS | ||
| Campione [2004] | Retro. | 120 | IA | Compromised | Seg.: 21 | 3 | 9.5 | 65 | 62 | NS | 2 | 19 | – | ||
| Keenan [2004] | Retro. | 201 | I | Compromised | Seg.: 54 | 4.8 | 5.6 | 67 (4-YSR) | 62 (4-YSR) | NS | 7.5 | 11.1 | NS | ||
| Martin-Ucar [2005] | Retro.; propensity matched study | 34 | I | N/R | Seg.: 17 | 5.8 | 5.8 | 64 | 70 | NS | 2 | 0 | NS | ||
| El-Sherif [2006] | Retro. | 784 | I | Compromised | Wedge: 122; Seg.: 85 | – | – | 54 | 40 | 0.0038 | 4.2 | 7.2 | 0.0204 | ||
| Chang [2007] | Retro.; SEER database | 10,761 | IA | N/R | Sublobar: 2,234 | – | – | 61.4 | 44.0 | <0.0001 | – | – | – | ||
| Iwasaki [2007] | Retro. | 86 | <2 cm | Mixed | Seg.: 31 | 0 | 0 | 73 | 70 | NS | 3.6 | 3.2 | NS | ||
| Kraev [2007] | Retro. | 289 | I | Compromised | Wedge: 74 | – | – | 5.8 years (MST) | 4.1 years (MST) | NS | – | – | – | ||
| Sienel [2007] | Retro. | 199 | IA | Compromised | Seg.: 49 | – | – | 83 | 67 | 0.01 | 5 | 16 | 0.005 | ||
| Kilic [2009] | Retro. | 184 (age >75) | I | Compromised | Seg.: 78 | 4.7 | 1.3 | 47 | 46 | NS | 4 | 6 | NS | ||
| Billmeier [2011] | Retro. | 679 | I-II | Mixed | Wedge: 120; Seg.: 35 | 1.9 | 7.1 | 57 | 49 | NS | – | – | – | ||
| Wolf [2011] | Retro. | 238 | ≤2 cm | Compromised | Wedge: 130; Seg.: 24 | 4 | 0. | 80 | 59 | 0.0027 | 8 | 16 | NS | ||
| Varlotto [2013] | Retro. | 411 | I | Compromised | Wedge: 79; Seg.: 14 | – | – | 64.5 | 54.5 | NS | 24.6 | 39.5 | NS | ||
| Altorki [2014] | Retro. | 347 | IA | Compromised | Wedge: 37; Seg.: 16 | 1 | 0 | 86 | 85 | NS | – | – | – | ||
| Okada [2014] | Retro. | 634 | IA | Mixed | Seg.: 155 | 0 | 94.1 (3-YSR) | 95.7 (3-YSR) | NS | 3.5 | 1.9 | – | |||
| Tsutani [2014] | Retro. | 239 | IA (>50% GGO) | N/R | Wedge: 93; Seg.: 56 | 0 | 0 | 97.6 | Wedge: 98.7; Seg.: 98.2 | NS | 0 | 0 | – | ||
NSCLC, non-small cell lung cancer; 5-YSR, 5-year survival rate; LCSG, Lung Cancer Study Group; Pros., prospective study; Seg., segmentectomy; Retro., retrospective study; NS, not significant; N/R, not reported; SEER, Surveillance, Epidemiology, and End Results; MST, median survival time; GGO, ground-glass opacity.